Manifest and Concealed Accessory Pathways e534 Management of Patients With Symptomatic Manifest or Concealed Accessory Pathways e535 6.1.1. Acute Treatment: Recommendations e535 6.1.2. Ongoing Management: Recommendations e536 6.2. Management of Asymptomatic Pre-Excitation . e537 6.2.1. PICOTS Critical Questions e537 Asymptomatic Patients With Pre-Excitation: Recommendations e538 Risk Stratification of Symptomatic Patients With Manifest Accessory Pathways: Recommendations e539 7. Atrial Flutter e539 7.1. Cavotricuspid Isthmus Dependent Atrial Flutter . e539 7.2. Non Isthmus-Dependent Atrial Flutters e540 7.3. Acute Treatment: Recommendations e541 7.4. Ongoing Management: Recommendations e542 8. Junctional Tachycardia e544 8.1. Acute Treatment: Recommendations e544 8.2. Ongoing Management: Recommendations e545 9. Special Populations e545 9.1. Pediatrics e545 9.2. Patients With Adult Congenital Heart Disease e549 9.2.1. Clinical Features e549 9.2.2. Acute Treatment: Recommendations e550 9.2.3. OngoingManagement:Recommendations e551 9.3. Pregnancy e553 9.3.1. Acute Treatment: Recommendations e553 9.3.2. Ongoing Management: Recommendations e554 9.4. SVT in Older Populations e555 Acute Treatment and Ongoing Management: Recommendation e555 10. Quality-of-Life Considerations e555 11. Cost-Effectiveness e555 12. Shared Decision Making e556 13. Evidence Gaps and Future Research Needs e556 References e557 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) e570 Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) e571 Appendix 3. Abbreviations e574 Preamble Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, based on systematic methods to evaluate and classify evidence, provide a cornerstone of quality cardio- vascular care. 